Gain Therapeutics, Inc. (GANX) Financials

GANX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 15.4 million 4.1 million
March 31, 2026 18.7 million 4.7 million
Dec. 31, 2025 22.8 million 4.3 million
Sept. 30, 2025 11.0 million 5.1 million

GANX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -4.7 million 566050
March 31, 2026 -4.7 million 403509
Dec. 31, 2025 -4.6 million 401667
Sept. 30, 2025 -4.9 million 460005

GANX Net Income

No data available :(

GANX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 13.1 million 220058 266188
March 31, 2026 16.5 million 273265 298756
Dec. 31, 2025 20.8 million 300084 331114
Sept. 30, 2025 8.8 million 298797 180936

GANX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 42.9 million
March 31, 2026 42.2 million
Dec. 31, 2025 33.0 million
Sept. 30, 2025 35.0 million

GANX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 5 2.1 million 2.5 million -
March 31, 2026 3 2.8 million 2.6 million 12303
Dec. 31, 2025 3 2.3 million 2.1 million -
Sept. 30, 2025 4 2.8 million 1.9 million -

GANX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 21303
Dec. 31, 2025 - -4.9 million
Sept. 30, 2025 - 22817

GANX

Price: $2.03

52 week price:
1.45
4.34

Earnings Per Share: -0.50 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 17900

Market Capitalization: 90.4 million

Links: